Acute promyelocytic leukemia: An experience from a tertiary care centre in north India

Indian Journal of Cancer

Volumn 48, Issue 3, 2011, Pages 316-322

  Bajpai, J ^a   Sharma, A ^a   Kumar, L ^a   Dabkara, D ^a   Raina, V ^a   Kochupillai, V ^a   Kumar, R ^a  

^a INSTITUTE ROTARY CANCER HOSPITAL   (India)

Author keywords

Acute promyelocytic leukemia; all trans retinoic acid; arsenic trioxide

Indexed keywords

ARSENIC TRIOXIDE; CYTARABINE; DAUNORUBICIN; MERCAPTOPURINE; METHOTREXATE; RETINOIC ACID;

ADOLESCENT; ADULT; AGED; ARTICLE; ATRA SYNDROME; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CHILD; CLINICAL ARTICLE; CONTINUOUS INFUSION; DIARRHEA; DISEASE COURSE; DRUG FATALITY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEMATURIA; HUMAN; HYPERTRANSAMINASEMIA; INDIA; MAINTENANCE THERAPY; MALE; MORTALITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRESCHOOL CHILD; PROMYELOCYTIC LEUKEMIA; QT PROLONGATION; RELAPSE; SCHOOL CHILD; SEPSIS; TERTIARY HEALTH CARE; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; ARSENICALS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INDIA; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; NEUTROPENIA; OXIDES; RECURRENCE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TRETINOIN;

EID: 80053991450     PISSN: 0019509X     EISSN: 19984774     Source Type: Journal    
DOI: 10.4103/0019-509X.84938     Document Type: Article

References (37)

1. Tallman MS, Nabhan C, Feusner JH, Rowe JM. Acute promyelocytic leukemia: Evolving therapeutic strategies. Blood 2002;99:759-67. (Pubitemid 34525534)
2. Kantarjian HM, Keating MJ, McCredie KB, Beran M, Walters R, Dalton WT, et al. A characteristic pattern of leukemic cell differentiation without cytoreduction during remission induction in acute promyelocytic leukemia. J Clin Oncol 1985;3:793-8. (Pubitemid 15062906)
3. Tallman M, Kwaan HC. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood 1992;79:543-53.
4. Rowley JD, Golomb HM, Dogherty C. 15/17 Translocation: A consistent chromosomal change in acute promyelocytic leukemia. Lancet 1977;1:549-50. (Pubitemid 8045927)
5. DeThe H, Chomienne C, Lanotte M, Degos L, Dejean A. The t (15; 17) translocation of acute promyelocytic leukemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature 1990;347:558-61.
6. Haung ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, et al. Use of all trans-retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988;72:567-72.
7. Castaigne S, Chomienne C, Daniel MT, Berger R, Fenaux P, Degos L, et al. All trans-retinoic acid as a differentiation therapy for acute promyelocytic leukemia. Blood 1990;76:1704-9.
8. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Eng J Med 1998;339:1341-8. (Pubitemid 28509343)
9. Sanz MA, Martin G, Gonzalez M, Gonzá lez M, Leoń A, Rayoń C, et al. Riskadapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and Anthracycline monochemotherapy: A multicenter study by the PETHEMA group. Blood 2004;103:1237-43. (Pubitemid 38168633)
10. Tallman MS, Andersen JW, Schiffer CA, Frederick R. Appelbaum FR, Feusner JH, et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997;337:1021-8. (Pubitemid 27430519)
11. Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E, et al. A randomized comparison of all trans retinoic acid followed by chemotherapy and ATRA plus chemotherapy and therole of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1999;94:1192-200. (Pubitemid 29380399)
12. Burnett AK, Grimwade D, Solomon E, Wheatley K, Goldstone AH. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: Result of the randomized MRC Trial. Blood 1999;93:4131-43. (Pubitemid 29279255)
13. Estey E, Thall PF, Pierce S, Kantarjian H, Keating M. Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine. J Clin Oncol 1997;15:483-90. (Pubitemid 27074214)
14. Sanz MA, Lo CF, Martin G, Avvisati G, Rayon C, Barbui T, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: A joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000;96:1247-53. (Pubitemid 30658450)
15. Lengfelder E, Reichert A, Schoch C, Haase D, Haferlach T, Löffler H, et al. Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: Effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group. Leukemia 2000;14:1362-70. (Pubitemid 30601354)
16. Mathews V, George B, Lakshmi KM, Viswabandya A, Bajel A, Balasubramanian P, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: Durable remissions with minimal toxicity. Blood 2006;107:2627-32.
17. Frankel SR, Eardley A, Lauwers G, Weiss M, Warrell RP Jr. The "retinoic acid syndrome" in acute promyelocytic leukemia. Ann Intern Med 1992;117:292-6.
18. Ohnishi K, Yoshida H, Shigeno K, Nakamura S, Fujisawa S, Naito K, et al. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann Intern Med 2000;33:881-5.
19. Westervelt P, Brown RA, Adkins DR, Khoury H, Curtin P, Hurd D, et al. Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Blood 2001;98:266-71.
20. Douer D, Tallman MS. Arsenic trioxide. New clinical experience with an old medication in hematologic malignancies. J Clin Oncol 2005;23:2396-410. (Pubitemid 46218734)
21. Mandelli F, Diverio D, Avvisati G, Lucigno A, Barbui T, Bernasconi C, et al. Molecular remission in PML/RAR aά - positive Acute Promyelocytic Leukemia by Combined All-trans retinoic acid and Idarubicin (AIDA) therapy. Blood 1997;90:1014-21. (Pubitemid 27314135)
22. Sanz MA, Martin G, Rayon C, Esteve J, Gonza lez M, Diaz-Mediavilla J, et al. A Modified AIDA Protocol With Anthracycline-Based Consolidation Results in High Antileukemic Efficacy and Reduced Toxicity in Newly Diagnosed PML/RARa-Positive Acute Promyelocytic Leukemia. Blood 1999;94:3015-21. (Pubitemid 29512705)
23. Rafael H, Raul AM, Fernanda R, Éderson R, Claudia T, Evandro M, et al. Clinical features and outcomes of 134 Brazilians with acute promyelocytic leukemia who received ATRA and anthracyclins. Haematologica 2007;92:1431-2.
24. George B, Mathews V, Poonkuzhali B, Shaji RV, Srivastava A, Chandy M. Treatment of children with newly diagnosed acute promyelocytic leukemia with arsenic trioxide: A single center experience. Leukemia 2004;8:1587-90. (Pubitemid 39386334)
25. Mathews V, Poonkuzhali B, Shaji RV, George B, Chandy M, Srivastava A. Arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: A single center experience. Am J Hematol 2002;70:292-9. (Pubitemid 34810506)
26. Mathews V, Thomas M, Srivastava VM, George B, Srivastava A, Chandy M. Impact of FLT3 mutations and secondary cytogenetic changes on the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with a single agent arsenic trioxide regimen. Haematologica 2007;92:994-5. (Pubitemid 350144251)
27. Mathew V, George B, Chendamara E. Lakshmi KM, Desire S, Balasubramanian P, et al. Single-Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute promyelocytic Leukemia: Long-Term Follow-Up Data. J Clin Oncol 2010;28:3866-71.
28. Advani SH, Nair R, Bapna A, Gladstone B, Kadam P, Saikia TK, et al. Acute promyelocytic leukemia: All-trans retinoic acid (ATRA) along with chemotherapy is superior to ATRA alone. Am J Hematol 1999;60:87-93. (Pubitemid 29047426)
29. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Woods WG, et al. Alltrans retinoic acid in acute promyelocytic leukemia: Long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 2002;100:4298-302. (Pubitemid 36001941)
30. Bourgeois E, Chevret S, Sanz M, Dombret H, Thomas X, Fey M, et al. Long-term follow-up of APL treated with ATRA and chemotherapy including incidence of late relapses and overall toxicity. Blood 2003;102:140a.
31. Avvisati G, Petti MC, Lo Cocco F, Testi AM, Fazi P, Specchia G, et al. The Italian way of treating acute promyelocytic leukemia: Final act. Blood 2003;102:142a.
32. Iland H, Bradstock K, Chong L, Springall F, Ayling J, et al. Results of the APML3 trial of ATRA, intensive idarubicin and triple maintenance combined with molecular monitoring in acute promyelocytic leukemia: A study by the Australasian Leukemia and lymphoma Group. Blood 2003;102:141a.
33. Jacomo RH, Melo R, Souto F, Mattos E, Oliveira C, Fagundes E, et al. Clinical features and outcome of 148 patients with acute promyelocytic leukemia in Brazil. Blood 2006;108:3326.
34. Ribeiro RC, Rego E. Management of APL in developing countries: Epidemiology, challenges and opportunities for international collaboration. Hematology Am Soc Hematol Educ Program 2006:162-8.
35. Asou N, Kishimoto Y, Kiyoi H, Okada M, Kawai Y, Tsuzukiet M, et al. A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RAR{alpha} transcript after consolidation therapy: The Japan Adult Leukemia Study Group (JALSG) APL97 study. Blood 2007;110:59-66 (Pubitemid 47026819)
36. Ono T, Takeshita A, Kishimoto Y, Kiyoi H, Okada M, Kawai Y, et al. Clinical Features and Outcomes of Elderly Patients with Acute Promyelocytic Leukemia (APL) - the Japan Adult Leukemia Study Group APL97 Study. Blood (ASH Annual Meeting Abstracts) 2010. 116: Abstract 1077.
37. Testi AM, Foa R, Tomei G, Lo Coco FL, Biondi A, Pession A, et al. GIMEMA-AIEOPAIDA Protocols for the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia (APL) In Children: Analysis of 247 Patients Enrolled In Two Sequential Italian Multicenter Trials. Blood (ASH Annual Meeting Abstracts) 2010 116: Abstract 871.